14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
XNCR vs ANAB: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, AnaptysBio, Inc. (ANAB) is the stronger overall head-to-head candidate over Xencor, Inc. (XNCR) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). XNCR carries a Unified Composite Score of 29.6/100 (SELL) at $35.61 (68.0x Forward P/E, -72.7% operating margin), whereas ANAB carries 46.7/100 (HOLD) at $45.18 (10.1x Forward P/E, 15.0% operating margin).
Growth vs. Quality Trade-Off: ANAB earns the overall head-to-head edge with a stronger Unified Composite Score (46.7/100 HOLD vs. XNCR 29.6/100 SELL) and 1.08β · 46% Vol risk profile, whereas XNCR leads top-line expansion (+454.9% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: XNCR trades in a Markup technical trend (BREAKOUT options phase, RSI 62.5); meanwhile ANAB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Biotechnology value chain with $1.4B market capitalization and 15.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ XNCR vs ANAB Key Questions & Quantitative Answers
As of Nov 16, 2026, AnaptysBio, Inc. (ANAB) is the stronger overall head-to-head candidate over Xencor, Inc. (XNCR) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). XNCR carries a Unified Composite Score of 29.6/100 (SELL) at $35.61 (68.0x Forward P/E, -72.7% operating margin), whereas ANAB carries 46.7/100 (HOLD) at $45.18 (10.1x Forward P/E, 15.0% operating margin). Growth vs. Quality Trade-Off: ANAB earns the overall head-to-head edge with a stronger Unified Composite Score (46.7/100 HOLD vs. XNCR 29.6/100 SELL) and 1.08β · 46% Vol risk profile, whereas XNCR leads top-line expansion (+454.9% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: XNCR trades in a Markup technical trend (BREAKOUT options phase, RSI 62.5); meanwhile ANAB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
XNCR leads the Growth & Scale pillar: XNCR posts +454.9% YoY revenue growth and +0.0% YoY earnings growth on $200M TTM revenue (-42.5% gross margin, -72.7% operating margin), compared with ANAB at -60.3% YoY revenue growth and -78.8% YoY earnings growth on $60M TTM revenue (N/A gross margin, 15.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), XNCR cumulative revenue shifted +225.0% while ANAB shifted +2200.0%. In operating R&D and SG&A reinvestment, XNCR deploys 30.2% of Rev ($61M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ANAB.
ANAB screens cheaper on headline valuation multiples. XNCR trades at 68.0x Forward P/E, 68.0x Trailing P/E, N/M PEG, and 14.8x EV/Revenue (-88.0% FCF margin), whereas ANAB trades at 10.1x Forward P/E, 19.7x Trailing P/E, N/M PEG, and 19.4x EV/Revenue (7.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against XNCR (-19.9% ROE) versus ANAB (-114.5% ROE) capital efficiency.
In options market volatility and institutional positioning, XNCR carries 79.0% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.21β · 87% Vol realized risk). By comparison, ANAB carries 92.7% implied volatility (19th %ile, Compressed (<25th %ile)), a 4.86x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.08β · 46% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.